静脉注射用免疫球蛋白药学特点和临床应用探索

宋钰, 都丽萍, 屈静晗, 梅丹

中国药学杂志 ›› 2021, Vol. 56 ›› Issue (5) : 417-421.

PDF(1012 KB)
中国药学杂志
PDF(1012 KB)
中国药学杂志 ›› 2021, Vol. 56 ›› Issue (5) : 417-421. DOI: 10.11669/cpj.2021.05.013
论著

静脉注射用免疫球蛋白药学特点和临床应用探索

  • 宋钰, 都丽萍, 屈静晗, 梅丹
作者信息 +

Pharmaceutical Characteristics and Clinical Application of Intravenous Immunoglobulin

  • SONG Yu, DU Li-ping, QU Jing-han, MEI Dan
Author information +
文章历史 +

摘要

目的 探究静脉注射用免疫球蛋白的特点及临床应用,旨在为临床用药提供全面、有效的参考。方法 通过以“静脉注射用免疫球蛋白”“免疫球蛋白”“IVIG”“immunoglobulin”为关键词,检索CNKI、万方、PubMed、Embase、Web of Science等国内外多个数据库近十年发表的期刊文献和国内外最新临床治疗指南,汇总静脉注射用免疫球蛋白信息,着重介绍静脉注射用免疫球蛋白临床使用的证据支持。结果 国内外静脉注射用免疫球蛋白制剂临床应用广泛,从作用机制、药动学特点、循证证据综合探究,对临床合理用药具有指导意义。结论 未来需要结合临床需求开展真实世界研究或临床试验研究,获得更多循证证据的支持,保障IVIG临床合理使用,让更多患者获益。

Abstract

OBJECTIVE To investigate intravenous immunoglobulin development characteristics and clinical application, and to provide comprehensive and effective references for clinical medication. METHODS The information of intravenous immunoglobulin was collected by searching the journal literature of CNKI, Wanfang, PubMed, Embase, Web of Science,and other domestic and foreign databases, and the latest relevant clinical treatment guidelines at home and abroad, and the evidence-based evidence and safety of the clinical use of gamma globulin for intravenous injection were emphasized. RESULTS Gamma globulin preparations for intravenous injection at home and abroad are widely used in clinical practice. Comprehensive investigation from the perspective of mechanism of action, pharmacokinetic characteristics, evidence-based evidence, and safety has guiding significance for clinical medication. CONCLUSION In the future, carry out real-world research or clinical trial research should be carried out combined with clinical needs to obtain more evidence-based support, ensure the rational use of IVIG in clinical practice, and benefit more patients.

关键词

静脉注射用免疫球蛋白 / 作用机制 / 药动学 / 药学特点 / 临床应用

Key words

intravenous immunoglobulins / mechanism / pharmacokinetic / pharmaceutical characteristics / clinical application

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
宋钰, 都丽萍, 屈静晗, 梅丹. 静脉注射用免疫球蛋白药学特点和临床应用探索[J]. 中国药学杂志, 2021, 56(5): 417-421 https://doi.org/10.11669/cpj.2021.05.013
SONG Yu, DU Li-ping, QU Jing-han, MEI Dan. Pharmaceutical Characteristics and Clinical Application of Intravenous Immunoglobulin[J]. Chinese Pharmaceutical Journal, 2021, 56(5): 417-421 https://doi.org/10.11669/cpj.2021.05.013
中图分类号： R969.3   

参考文献

[1] Ch.P(2020) Vol Ⅲ(中国药典2020年版.三部)[S]. 2020:269-270.
[2] EP 9.0[S]. 2016: 2687-2688.
[3] USP 40-NF 35[S]. 2015: 4409.
[4] CHAIGNE B, MOUTHON L. Mechanisms of action of intravenous immunoglobulin[J]. Transfus Apher Sci, 2017, 56(1): 45.
[5] Ch.P(2020) Vol Ⅲ(中国药典2020年版.三部)[S]. 2020
[6] MARTINEZ T, GARCIA-ROBLEDO J E, PLATA I, et al. Mechanisms of action and historical facts on the use of intravenous immunoglobulins in systemic lupus erythematosus[J]. Autoimmun Rev, 2019, 18(3): 279.
[7] POTTER M, STOCKLEY R, STORRY J, et al. ABO alloimmunisation after intravenous immunoglobulin infusion[J]. Lancet, 1988, 1(8591): 932-933.
[8] KOLEBA T, ENSOM M H. Pharmacokinetics of intravenous immunoglobulin: a systematic review[J]. Pharmacotherapy, 2006, 26(6): 813-827.
[9] NOYA F J, RENCH M A, COURTNEY J T, et al. Pharmacokinetics of intravenous immunoglobulin in very low birth weight neonates[J]. Pediatr Infect Dis J, 1989, 8(11): 759-763.
[10] FDA. Immune Globulins.[EB/OL]. (2019-08-16) [2020-07-21]. https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/immune-globulins.
[11] DESPOTOVIC J M, LAMBERT M P, HERMAN J H, et al. RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME)[J]. Transfusion, 2012, 52(5):1126-1136;quiz 1125.
[12] LAKSHMANAN S, CUKER A. Contemporary management of primary immune thrombocytopenia in adults[J]. J Thromb Haemost, 2012, 10(10):1988-1998.
[13] MUELLER-ECKHARDT C, KIEFEL V. High-dose IgG for post-transfusion purpura-revisited[J]. Blut, 1988, 57(4):163-167.
[14] BUX J, BEHRENS G, JAEGER G, et al. Diagnosis and clinical course of autoimmune neutropenia in infancy: analysis of 240 cases[J]. Blood, 1998, 91(1):181-186.
[15] HILGARTNER M W, BUSSEL J. Use of intravenous gamma globulin for the treatment of autoimmune neutropenia of childhood and autoimmune hemolytic anemia[J]. Am J Med, 1987, 83(4A):25-29.
[16] HUBER A M, KIM S, REED A M, et al. Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash[J]. J Rheumatol, 2017, 44(1):110-116.
[17] MAEDA H, FURONAKA O, MATSUSHIMA K, et al. Successful treatment of ‘malignant rheumatoid arthritis’ in Japan with pooled intravenous immunoglobulin[J]. Rheumatology (Oxford), 2001, 40(8):955-956.
[18] ARNAL C, PIETTE J C, LEONE J, et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases[J]. J Rheumatol, 2002, 29(1):75-83.
[19] PATWA H S, CHAUDHRY V, KATZBERG H, et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders report of the therapeutics and technology assessment subcommittee of the american academy of neurology[J]. Neurology, 2012, 78(13):1009-1015.
[20] DIENER H C, HAUPT W F, KLOSS T M, et al. A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barre syndrome[J]. Eur Neurol, 2001, 46(2):107-109.
[21] Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Plasma exchange/sandoglobulin guillain-barre syndrome trial group[J]. Lancet, 1997, 349(9047):225-230.
[22] BRIL V, ILSE W K, PEARCE R, et al. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barre syndrome[J]. Neurology, 1996, 46(1):100-103.
[23] HUGHES R A, SWAN A V, VAN DOORN P A. Intravenous immunoglobulin for Guillain-Barre syndrome[J]. Cochrane Database Syst Rev, 2014(9): D2063.
[24] ZINMAN L, NG E, BRIL V. Ⅳ immunoglobulin in patients with myasthenia gravis: a randomized controlled trial[J]. Neurology, 2007, 68(11):837-841.
[25] PARKS T, WILSON C, CURTIS N, et al. Polyspecific intravenous immunoglobulin in clindamycin-treated patients with streptococcal toxic shock syndrome: a systematic review and Meta-analysis[J]. Clin Infect Dis, 2018, 67(9):1434-1436.
[26] JENSON H B, POLLOCK B H.The role of intravenous immunoglobulin for the prevention and treatment of neonatal sepsis[J]. Semin Perinatol, 1998, 22(1):50-63.
[27] EMANUEL D, CUNNINGHAM I, JULES-ELYSEE K, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin[J]. Ann Intern Med, 1988, 109(10):777-782.
[28] LJUNGMAN P, ENGELHARD D, LINK H, et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group[J]. Clin Infect Dis, 1992, 14(4):831-835.
[29] LEHNERS N, SCHNITZLER P, GEIS S, et al. Risk factors and containment of respiratory syncytial virus outbreak in a hematology and transplant unit[J]. Bone Marrow Transplant, 2013, 48(12):1548-1553.
[30] GHOSH S, CHAMPLIN R E, ENGLUND J, et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin[J]. Bone Marrow Transplant, 2000, 25(7):751-755.
[31] ALI M B. Treating severe acute respiratory syndrome with hyperimmune globulins[J]. Hong Kong Med J, 2003, 9(5):391-392.
[32] CHIANG C H, CHEN H M, SHIH J F, et al. Management of hospital-acquired severe acute respiratory syndrome with different disease spectrum[J]. J Chin Med Assoc, 2003, 66(6):328-338.
[33] LEW T W, KWEK T K, TAI D, et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome[J]. JAMA, 2003, 290(3):374-380.
[34] ARABI Y M, ARIFI A A, BALKHY H H, et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection[J]. Ann Intern Med, 2014, 160(6):389-397.
[35] KAPOOR M, PRINGLE K, KUMAR A, et al. Clinical and laboratory findings of the first imported case of Middle East respiratory syndrome coronavirus to the United States[J]. Clin Infect Dis, 2014, 59(11):1511-1518.
[36] LUKE T, WU H, ZHAO J, et al. Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo[J]. Sci Transl Med, 2016, 8(326):326ra21.
[37] National Health Commission of the People's Republic of China. Clinical management of human infection with novel coronavirus(COVID-2019)(Interim guidance v7). [EB/OL]. ( 2020-03-03) [2020-07-21]. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
[38] LI T S, CAO W,WENG L, et al. Diagnosis and clinical management of 2019 novel coronavirus (2019-nCoV) infection: an operational recommendation of Peking Union Medical College Hospital(2.0) [J]. Emerg Microbes Infect, 2020,9(1):582-585.
[39] XIE Y, CAO S, LI Q, et al. Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19[J]. J Infect, 2020, 81(2):318-356.
[40] SHAO Z, FENG Y, ZHONG L, et al. Clinical efficacy of intravenous immunoglobulin therapy in critical patients with COVID-19: a multicenter retrospective cohort study[J]. Clin Transl Immunol, 2020, 9(10): e1192.
[41] CAO W, LIU X, BAI T, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019[J]. Open Forum Infect Dis, 2020, 7(3):ofaa102.
[42] Chinese Clinical Trial Registry. Index of clinical novel coronavirus pneumonia (updated to 3:25 July 20, 2020, Beijing time).[EB/OL]. (2020-07-21) [2020-07-21]. http://www.chictr.org.cn/showproj.aspx?proj=51072.
[43] Octapharma USA. FDA Approves Octapharma USA Investigational New Drug Application for Severe COVID-19 Patients. [EB/OL]. (2020-05-20) [2020-07-21]. https://www.octapharmausa.com/en/news-contact/news-single-view.html?tx_ttnews%5Btt_news%5D=1148&cHash=272a8924d90e94efcabf0d2fe596271d.
[44] LIU J, ZENG Y P, HE C X, et al. Corticosteroids plus intravenous immunoglobulin in the treatment of 7 cases with Stevens-Johnson syndrome and toxic epidermal necrolysis [J]. Med J Peking Union Med Coll Hosp(协和医学杂志), 2012, 3(4): 381-385.
[45] KRAJEWSKI A, MAZUREK M J, MLYNSKA-KRAJEWSKA E. Successful therapy of recurrent toxic epidermal necrolysis using total plasma exchange, continuous venovenous hemodiafiltration, and intravenous immunoglobulin-case report[J]. Dermatol Ther, 2020,33(4):e13442.
[46] ZIMMERMANN S, SEKULA P, VENHOFF M, et al. Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and Meta-analysis[J]. Jama Dermatol, 2017, 153(6):514-522.
[47] HOLM J G, IVYANSKIY I, THOMSEN S F. Use of nonbiologic treatments in antihistamine-refractory chronic urticaria: a review of published evidence[J]. J Dermatol Treat, 2018, 29(1):80-97.
[48] WANG T, MA D L, LIU Y H, et al. Epidermolysis bullosa acquisita: a case report [J]. J Clin Dermatol(临床皮肤科杂志), 2009, 38(10):664-666.
[49] WETTER D A, DAVIS M D, YIANNIAS J A, et al. Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience[J]. Mayo Clin Proc, 2005, 80(1): 41-47.
[50] EMRE S.Intravenous immunoglobulin treatment: where do dermatologists stand?[J]. Dermatol Ther, 2019, 32(3): e12854.
[51] DU Z Y, YUAN J. Blood products industry report: four times industry, selected leader [R]. Pacific Securities, 2020.
PDF(1012 KB)

Accesses

Citation

Detail
段落导航
相关文章

/

〈 〉